Last reviewed · How we verify
Feces collection
At a glance
| Generic name | Feces collection |
|---|---|
| Sponsor | Uppsala University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Syncope
- Vessel puncture site bruise
- Vessel puncture site swelling
- Dizziness
- Epistaxis
- Non-serious, Anticipated, Adverse Event
- Vessel puncture site haemorrhage
- Vessel puncture site pain
- Vessel puncture site rash
- Dermatitis contact
- Vessel puncture site hypoaesthesia
- Concussion
Key clinical trials
- Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (PHASE1)
- Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (PHASE2)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis (PHASE3)
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) (PHASE2)
- Blood Donor CVD 5000 (PHASE4)
- Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV) (NA)
- MIMICC Study in Patients With Colorectal Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Feces collection CI brief — competitive landscape report
- Feces collection updates RSS · CI watch RSS
- Uppsala University portfolio CI